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Summary
We describe 36 patients with splenic marginal zone lymphoma (SMZL)
with transformation (SMZL-T), including 15 from a series of 84 patients
with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21
diagnosed with SMZL-T in other centres. In the HCB cohort, the cumula-
tive incidence of transformation at 5 years was 15%. Predictors for trans-
formation were cytopenias, hypoalbuminaemia, complex karyotype (CK)
and both the Intergruppo Italiano Linfomi (ILL) and simplified Hae-
moglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lym-
phadenopathy (HPLL)/ABC scores (P < 005). The only independent
predictor for transformation in multivariate analysis was CK [hazard ratio
(HR) 4025, P = 005]. Patients with SMZL-T had a significantly higher
risk of death than the remainder (HR 389, P < 0001). Of the 36 patients
with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-
cell lymphoma, 71% with a non-germinal centre phenotype. The main fea-
tures were B symptoms, lymphadenopathy, and high serum LDH. CK was
observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation
detected abnormalities of MYC proto-oncogene, basic helix-loop-helix tran-
scription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6
in six of 14 (43%). In all, 21 patients received immunochemotherapy, six
chemotherapy, one radiotherapy and three splenectomy. The complete
response (CR) rate was 61% and the median survival from transformation
was 492 years. Predictors for a worse survival in multivariate analysis were
high-risk International Prognostic Index (HR 5294, P = 0016) and lack of
CR (HR 267, P < 0001).
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Introduction
Splenic marginal zone lymphoma (SMZL) is an uncommon
low-grade lymphoma that accounts for ~2% of all lympho-
proliferative disorders.1,2 SMZL usually has an indolent
course and a favourable outcome with a median overall sur-
vival (OS) of >10 years.2–4 Risk stratification is based on the
scores proposed by the Intergruppo Italiano Linfomi (IIL)5
and the International Splenic Lymphoma Study Group
(ISLSG) simplified Haemoglobin, Platelet count, lactate
dehydrogenase (LDH) and extrahilar Lymphadenopathy
(HPLL/ABC),6 which consider low-, intermediate- and high-
risk groups.
Despite the indolent behaviour of SMZL, about 10–15%
of patients manifest aggressively and undergo transformation,
usually to a diffuse large B-cell lymphoma (DLBCL).7–10
Although transformation of low-grade lymphomas to high-
grade B-cell neoplasms is well-known, the information of
such a scenario in SMZL regarding the incidence and factors
associated with transformation and the clinico-biological fea-
tures and outcome of these patients is limited.10,11 There
have been few reports of patients with SMZL with confirmed
transformation,10–13 but either these included a small number
of patients, or all types of marginal zone-derived lymphomas
with only a few of splenic origin. In addition, some reports
were focussed on the pathological features or only described
the incidence with few details on the clinico-biological char-
acteristics at transformation.12,13
In the present study, we retrospectively analysed 36
patients with SMZL who underwent transformation (SMZL-
T), during the disease course or rarely at diagnosis. The aims
of the present study were: (i) to describe the clinical and
cytogenetic features, response to therapy and outcome from
the time of transformation of these patients, and (ii) to
assess the incidence and clinical and biological factors that
could predict transformation in a cohort of 84 patients con-
secutively diagnosed with SMZL in a single institution.
Patients and methods
Patients
A total of 36 patients from different centres with histologically
confirmed transformation of SMZL (SMZL-T) were included
in the study. In all, 15 were retrieved from a series of 84
patients with SMZL consecutively diagnosed at the Hospital
Clinic of Barcelona (HCB) between March 1994 and August
2017, and 21 were referred from other institutions of the
Spanish Lymphoma Group (GELTAMO) and UK. The cohort
from the HCB was used to estimate the incidence and predic-
tors of transformation. The following clinical and biological
data at diagnosis and at the time of transformation were
recorded: age; gender; performance status according to the
Eastern Cooperative Oncology Group Performance Status
(ECOG PS) scale and presence of B symptoms; haematological
and biochemical parameters, serum LDH and b2-
microglobulin (B2M) levels, monoclonal component and
autoimmune screen; number and size of nodal and extra-
nodal involvement; presence of splenomegaly; degree of bone
marrow (BM) infiltration; Ann Arbor Stage and presence of
bulky disease (defined as a tumour diameter >7 cm); prognos-
tic scores according to the HPLL/ABC and IIL for SMZL, and
the International Prognostic Index (IPI) in patients with
SMZL-T; cytology, immunophenotype, histology; conventional
cytogenetics and fluorescence in situ hybridisation (FISH);
treatment modality; relapse, survival and causes of death.
Response at the end of initial treatment of SMZL, and
after each line of therapy was assessed according to conven-
tional criteria based on the 2008 SMZL guidelines by com-
puted tomography (CT) scans, BM biopsy and aspirate,
peripheral blood (PB) cytology and flow cytometry.14 Com-
plete response (CR) was defined as the complete resolution
of organomegaly and disease-related symptoms, normalisa-
tion of blood counts without evidence of BM or PB infiltra-
tion by clonal B cells. Partial response (PR) was considered
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when there was a ≥50% improvement in all features. All the
other situations were considered as no response (NR).
Response duration was calculated from the time of response
assessment for patients in CR and PR to relapse/progression.
The responses to therapy in patients with SMZL-T were eval-
uated with a CT scan and BM biopsy or aspirate according
to conventional criteria for lymphomas.15 In 16 (44%) of the
patients with SMZL-T, a positron emission tomography scan
was also available to assess the response. CR was considered
as the total disappearance of tumour masses, disease-related
symptoms, and normalisation of the initial abnormal tests
for ≥1 month. PR was defined when the tumour mass
decreased by ≥50% along with the disappearance of disease-
related symptoms. Disease relapse or progression was defined
as the appearance of new symptoms or signs of the disease
demonstrated by tissue biopsy, or other appropriate studies.
OS and progression-free survival (PFS) were calculated
according to standard definitions.16 All patients gave
informed consent, according to the ethical standards of the
ethic committees of the different institutions.
Cytology, histology review, immunohistochemistry (IHC)
and cytogenetics
The diagnosis of SMZL was made according to the Interna-
tional Extranodal Lymphoma Study Group (IELSG) guideli-
nes and World Health Organization (WHO),14,17 based on
morphology and flow cytometry of PB lymphocytes and BM
aspirate and biopsy and/or splenic histology, with the aid of
IHC. The diagnostic material in the HCB cohort was splenic
histology in 52; lymph node biopsy in three; and BM and PB
cytology, flow cytometry and cytogenetics in 57.
The diagnosis of SMZL-T was made on tissue histology
and IHC of the involved site in all patients, according to the
updated WHO classification criteria.17 All the histological
material was reviewed by D.M., E.C. and E.M. To assess the
clonality of the transformed samples, the FR1 region of the
immunoglobulin heavy-chain variable-region (IGHV) was
amplified using primers corresponding to the BIOMED-2
multiplex polymerase chain reaction protocol.
Cytogenetic studies were carried out on G-banded chro-
mosomes in 77 patients. Karyotypes were described accord-
ing to the International System for Human Cytogenetic
Nomenclature (ISCN).18 Complex karyotype (CK) was
defined by the presence of at least three clonal chromosomal
abnormalities, the abnormalities detected only by FISH were
not considered for the definition of CK. FISH studies were
performed in 56 patients using MetaSystems FISH probes
and hybridisation and detection were performed according
to the manufacturer’s protocols.
Statistical analysis
Differences among the patients’ characteristics were assessed
using the chi-square test (two-tailed), the Student’s t-test, or
non-parametric tests, when necessary. The actuarial survival
analysis was performed using the Kaplan–Meier method and
the differences assessed by the log-rank test. Multivariate
analyses were performed with the step-wise proportional haz-
ards Cox model. Cumulative incidence was used to assess the
risk of transformation in the 84 patients with SMZL from
the HCB and compared by use of Gray’s test. Multivariate
analysis was performed by Fine–Gray test. CR achievement
and transformation were considered time-dependent vari-
ables and as such analysed by means of landmark, Mantel–
Byar test or Cox model with time-dependent variable. A
P < 005 was considered statistically significant.
Results
Incidence and risk of transformation
The incidence of and risk factors for transformation were
evaluated in the 84 patients in the HCB cohort, where 15
patients eventually developed SMZL-T at a median (range)
of 60 (0–228) years from diagnosis. The main disease fea-
tures of these 84 patients at diagnosis are detailed in
(Table SI). The median (range) age was 63 (32-91) years.
Prognostic scores according to the IIL and HPLL/ABC strati-
fication showed that two-thirds of the patients had
intermediate- or high-risk SMZL scores.
Cytogenetic studies at diagnosis in the patients that devel-
oped transformation are summarised in Table I. The cytoge-
netic results for the 54 patients who did not develop
transformation are shown in Table SII. Aberrant karyotypes
were found in 32/54 (59%) patients. The recurrent 7q dele-
tion was detected in 18 (37%) patients by karyotype and as a
single abnormality in 10/18 (56%). In case 43, with a t
(1;18;14)(q41;q21;q32), in which IGH-B-cell leukaemia/lym-
phoma 2 (BCL2) rearrangement was demonstrated by FISH
in 93% of cells, the spleen histology at diagnosis was studied
exhaustively and other diagnosis such as follicular lymphoma
(FL), mucosa-associated lymphoid tissue (MALT) and nodal
marginal zone lymphomas were ruled out. A CK was found
in only seven of 54 (13%) patients.
At diagnosis of SMZL, 33 of the 84 (39%) patients
required treatment, while a watchful-waiting policy was
adopted in the remaining 51 (61%). Front-line therapy is
detailed in Table SI. After that, 27 of 33 (82%) patients
achieved a response: nine (27%) CR, 18 (54%) PR; and six
(18%) NR.
After a median (range) follow up of 667 (02–228) years,
37 of 84 (44%) patients with SMZL have died. The median
OS was 122 years with a 10-year OS of 63% [95% confi-
dence interval (CI) 51–75] (Fig S1). Factors predicting for a
shorter OS in univariate analysis are shown in Table SIII. In
multivariate analysis using the Cox regression test, the initial
variables that significantly predicted a shorter OS were age
>60 years [hazard ratio (HR) 748, P = 0001] and CK (HR
374, P = 0011).
Features and outcome of SMZL in transformation
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Table I. Cytogenetics at diagnostic and at the time of transformation in the 36 patients with splenic marginal zone lymphoma with transforma-
tion (SMZL-T).
Case Sample Sample time Cytogenetics CK FISH
1 PB DX 46,XY,t(1;14)(p36;q32),t(1;14;16)(q11;q32;p12),del(7)(q31q36)
[4]/46,idem, der(5)t(5;6)(q21;q25), der(6)ins(6;5)(q25; q21q35)
[6]/46,idem,del(5)(q21q23)[4]/46,XY[6]
Yes
1 PB/LN T (*PB) 47,XY,add(1)(q11),del(1)(p?32p?36),-5,-6,del(7)(q31q36),-
9, der(12)t(5;12)(q13;p11),add(14)(q32)x2,+4mar[9]
Yes (LN) MYC, BCL2: Normal
2 PB DX 47,XY,del(6)(q23q24),del(7)(q31q32),del(13)(q12q14),+mar
[cp19]/46,XY[1]
Yes IGH-CCND1: Normal
3 PB T 47,X,-X,del(1)(p22),+add(3)(p13),+5,add(6)(q24),del(7)(q32q36),
t(14;18)(q32;q21)[16]
Yes
4 PB DX 46,XX,trp(1)(q23q32)[19]/46,XX[1]
4 Spleen DX 46,XX,trp(1)(q23q32),add(3)(p25),add(16)(q?23)[cp5] Yes





5 BM DX 46,XX(20)
5 LN/*PB T (PB) 46-47,XX,?dup(1)(q21q32),del(7)(q21q31),add(8)(p23),add
(8)(q24),+10,del(11)(q22q23),del(12)(q23q24),del(18)
(p11),+mar1,+mar2[cp8]/46,XX,inv(17)(p11q21)[2]
Yes (*PB) 7q31: IGH-CCND1, MYC:
Normal
7 PB DX 46,XX[20]
7 Spleen DX 46,XX,del(7)(q22q32)[1],add14(q32)[3][cp3]/46,XX[27] 7q31:deletion
7 *PB T *46,XX,?dup(3)(q26q26),del(7)(q22q32),del(11)(q22q23)[cp6]/46,
XX[6]
Yes
7 LN T 46,XX,?dup(3)(q26q26),del(7)(q22q32),del(11)(q22q23)[cp6]/46,
XX[6]
Yes 7q31: deletion; BCL2, BCL6, MYC:
Normal
8 LN T 46,XY,del(7)(q22q32)[4]/48,XY,+3,del(3)(p12p14),+5,del(7)
(q22q32)[2]/46,XY[14]
Yes MYC: amplification; BCL2, BCL6:
Normal
9 PB DX 48,XY,+3,del(3)(q23q27),i(6)(p10),+18[17]/46,XY[3] Yes
9 *PB T *48,XY,+3,del(3)(q23q27), i(6)(p10),add(12)(p13),del(14)
(q24q32),+18,del(20)(q?11q?13)[15]
Yes BCL2, BCL6, MYC: Normal
10 PB DX 46,XX[20] ATM, 13q143.3, TP53: Normal;
CEP12: trisomy
10 *PB T *46,XX[20] CEP12: trisomy 12; del 6q; BCL2,
BCL6, MYC, ATM, TP53, 13q143,
IGH-CCND1, IGH-BCL2: Normal
11 PB DX 46,XY,del(20)(q12q13)[4]/46,XY[16] 7q321: Normal
11 LN/*BM T (*BM) 46,XY,del(20)(q12q13)[4]/46,XY[16] (LN) MYC rearranged: BCL2, BCL6:
gain/amplification
12 *PB T *46,XY[20] TP53: deletion; BCL2, BCL6, MYC,
7q31: Normal
13 PB DX 46,XX,dup(1)(q21q24)[3]/47,idem,+add(3)(q26),add(14)(q32)[3]/
46,XX[8]
Yes IGH: 30% rearranged; IGH-BCL2:
normal
13 PB T *49-50,XX,dup(1)(q21q24)x2,+3,+5,+7,+add(14)(q32)[cp7]/46,
XX[7]
Yes
14 *PB T *46,XY[20] IGH-CCND1: Normal
15 PB DX 46,XX[20]
15 PB T *46,XX,?del(11)(q22q23)[3]/45,idem,-X[1]/45,X,-X[5]/46,XX[12] Yes ATM, TP53, CEP12, 13q143:
Normal
16 PB DX 46,XY[18] IGH-CCND1, ATM, TP53, CEP12,
13q143: Normal
16 *PB T *46,XY[18] BCL2, BCL6, MYC: Normal
17 PB DX 46,XX,i(3)(q10)[4]/46,XX[16]
17 *PB T *46,XX,i(3)(q10)[4]/46,XX[4]
18 PB DX 46,XX,i(3)(q10)[4]/46,XX[12]
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The cumulative incidence of transformation at 5 years from
diagnosis was 15% (95% CI 7–23) (Figure 1A). Variables pre-
dicting a higher risk of transformation in the univariate analy-
sis were haemoglobin level of <100 g/l (P = 003), lymphocyte
count of <0.8 9 109/l (P = 0032), platelet count of
<100 9 109/l (P = 003), albumin of <35 g/l (P < 005) and
CK (P = 0026). In addition, intermediate- or high-risk IIL
(P = 0008) and high-risk HPLL (P = 0038) predicted higher
risk of transformation (Figure 1B, C). A watchful-waiting pol-
icy at diagnosis did not significantly influence the risk of
transformation. In multivariate analysis the only initial vari-
able that significantly predicted risk of transformation was
having a CK at diagnosis (HR 402, P = 005).
Finally, when comparing the survival of SMZL-T with that
of the patients that did not transform, patients with SMZL-T
had a significantly shorter OS (HR 3894, 95% CI 1816–
8350; P < 0001) as estimated by the Mantel–Byar test.
Clinico-biological features of SMZL at transformation
As already mentioned, 21 patients with SMZL-T were
referred from other institutions (whose initial features at
diagnosis are detailed in Table SIV) and 15 from the
HCB cohort constituted the 36 patients with SMZL-T
whose main clinico-biological features at the time of
transformation are detailed in Table II. In five patients,
the transformation occurred at diagnosis and in the
remaining 31 at follow-up at one or several sites (detailed
in Table II).
Most patients were aged >60 years, had anaemia and
advanced stage with lymph node enlargement, B symptoms
and high serum LDH as well as B2M levels (Table II). His-
tology of the tissue where transformation occurred showed
a DLBCL in 35 patients and Hodgkin lymphoma (HL) in
one. By IHC, the neoplastic cells in the patients with
DLBCL expressed B-cell antigens [cluster of differentiation
(CD)20, CD79, paired box 5 (PAX5)] and were negative for
CD3 and CD5. CD10 was positive in four patients, CD43 in
five, and CD23 in one. Immunoglobulin (Ig)D expression
was tested in 13 patients and seven were negative. Four of
these seven IgD-negative patients were previously positive
in the spleen of the low-grade SMZL. The Hans algorithm
was used to determine the cell of origin in 17 (47%) of the
patients with DLBCL with available data, and 12 (71%)
Table I. (Continued)
Case Sample Sample time Cytogenetics CK FISH
18 *PB T *46,XX,i(3)(q10)[6]/46,XX[17] BCL6: gain; 9p213: biallelic
deletion; IGH-CCND1 and IGH-
BCL2: Normal
19 Spleen/ LN T ND BCL2, BCL6, MYC: Normal
20 PB DX 47,XX,del(7)(q21q32),+19[15]/46,XX[4] 7q31: deletion
21 Spleen DX 46,XX,del(6)(q21q27)[3]/46,XX[17] 7q31, IGH-CCND1, IGH-BCL2:
Normal
21 LN T ND MYC: gain, BCL6: gain/rearranged;
IGH: rearranged, TP53: Normal
23 LN T MYC: amplification; BCL6: Normal
24 PB DX 50,XY,+5,+12,+19,+22[5]/46,XY[15] Yes
25 LN DX 46,XY,del(7)(q21q36)[1]/46,XY[22] 7q32: 47% deletion; IGH: Normal
25 Spleen T ND 7q32: 22% deletion
26 Spleen DX ND IGH-CCND1, API-MALT1 BCL2:
Normal
26 Spleen T ND 7q31: deletion; BCL2, BCL6, MYC:
Normal
27 LN T BCL6, BCL2, MYC: Normal
28 BM DX IGH-CCND1, ATM, TP53, CEP12,
13q143: Normal
33 PB DX 51,XX,+3,+8,+11,+18,+18[4]/51,XX,+3,+8,+der(11)add(11)
(q23),+18,+18[4]/46,XX[29]
Yes CCND1: gain; 7q31: Normal
33 PB T *50,X,+der(3),+8,+11,+18[2]/51,idem,+18[1]/46,XX[17] Yes BCL2, BCL6, MYC: amplified; 7q31,
CCND1-IGH, ATM, TP53, CEP12,
13q143: Normal
35 Spleen T BCL2, MYC: Normal
BM, bone marrow; CK, complex karyotype; DX, diagnosis; LN, lymph node; ND, not done; PB, peripheral blood; T, transformation; WCP,
whole-chromosome painting.
7q deletions/alterations are highlighted in bold font.
*Indicates that the karyotype or FISH have been performed at the time of transformation but in the non-transformed sample.
Features and outcome of SMZL in transformation
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showed a non-germinal centre (non-GCB) B-cell phenotype
and the remaining five (29%) a GCB phenotype. Tumour
cell proliferation was high, with a median (range) Ki-67
expression of 80 (40–100)%. p53 expression was positive in
four of nine (44%) patients and Epstein–Barr virus (EBV)
was demonstrated by EBV-encoded small nuclear RNAs
(EBERs), Epstein–Barr nuclear antigen (EBNA) and/or
latent membrane protein 1 (LMP1) in one of the nine
(11%). A clonal relationship could be demonstrated in the
29 patients analysed. In the three patients in whom trans-
formation was diagnosed in the spleen, there was a con-
comitant remaining low-grade SMZL component. One of
these three patients was diagnosed as HL with CD30+,
CD15+, CD79+, CD20– and EBV– Reed–Sternberg cells. The
other two patients had large areas of DLBCL in the spleen
with a residual minor small cell component. Therefore,
these patients were not merely SMZL with the presence of
scattered large cells.
Fig 1. Risk of transformation from diagnosis in the 84 patients with SMZL from the HCB . (A) Cumulative incidence of histological transforma-
tion, (B) Cumulative incidence according to ILL risk score, and (C) Cumulative incidence according to HPLL/ABC risk score. HBC, Hospital
Clinic of Barcelona; HPLL, Haemoglobin, Platelet count, lactate dehydrogenase and extrahilar Lymphadenopathy; ILL, Intergruppo Italiano Lin-
fomi; SMZL, splenic marginal zone lymphoma. [Colour figure can be viewed at wileyonlinelibrary.com]
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Conventional Cytogenetics and FISH of SMZL at
transformation
Information on conventional cytogenetics at the time of trans-
formation or at diagnosis was available in 22 patients
(Table I). Abnormal karyotypes were detected in 18/22 (82%)
patients and these included seven with a deletion of 7q arm
already present at diagnosis. Overall 7q deletion was detected
in 35% of the patients (one only by FISH). Other recurrent
abnormalities were add(14)(q32), t(14;18)(q32;q21), gains of
1q, 3q, trisomy 5, trisomy 18, and deletions of 6q and 11q. A
CK was found in 12/22 (55%) patients and these comprised
seven with CK already present at diagnosis and five that
acquired the CK in the transformed sample (Table I).
FISH analysis forMYC proto-oncogene, basic helix-loop-helix
transcription factor (MYC), BCL2 or BCL6 genes in the trans-
formed tissue showed abnormalities in six of 14 (43%) patients.
BCL6 rearrangement plus gain (one patient), BCL6 gain/amplifi-
cation (three), MYC rearrangement (one), MYC gain/amplifica-
tion (four), and BCL2 gain/amplification (two). Additionally, a
17p/tumour protein p53 (TP53) deletion was detected only by
FISH in one patient (case 12), and in a second patient FISH anal-
ysis showed a 9p21/CDKN2A homozygous deletion (case 18).
Therapy of SMZL-T
Treatment data at the time of transformation was as follows:
26 patients received immunochemotherapy with rituximab
(R): 21 R-CHOP (R plus cyclophosphamide, doxorubicin,
vincristine, prednisone), two R-CVP (R plus cyclophos-
phamide, vincristine, and prednisone), three R-ESHAP (R
plus etoposide, methylprednisolone, cytarabine and cisplatin);
six chemotherapy: four CHOP, one MINE (mesna, ifos-
famide, mitoxantrone and etoposide) plus ESHAP, one FCM
(fludarabine, cyclophosphamide, mitoxantrone); and one
patient was treated with local radiotherapy. Four of these 33
patients who received systemic treatment had been previously
splenectomised, where the diagnosis of transformation had
been made. Three other patients did not receive systemic
treatment and had only splenectomy. Of these three patients,
one was not further treated, one died after diagnostic
splenectomy (HL) and one was lost to follow-up. The
response was consolidated with autologous stem cell trans-
plantation (ASCT) in three patients. Of the 36 patients who
had systemic treatment or splenectomy, 35 were assessable
for response. Of these, 22 (61%) patients achieved a CR,
while 13 did not respond. Out of 22 responders, 12 continue
in CR at a median follow-up of 59 months, eight eventually
relapsed and one died from therapy-related acute myeloid
leukaemia while still in remission of the lymphoma.
Outcome from transformation of the 36 patients with
SMZL-T
A total of 20 patients with SMZL-T (56%) eventually died
and the cause of death was lymphoma related in 19 and
acute myeloid leukaemia in the remaining. The median sur-
vival from the time of transformation (SFT) of the 36
patients with SMZL-T was 492 years, with a 5-year SFT of
46% [95% confidence interval (CI) 27–65] (Figure 2A). The
variables predicting poor SFT were age >60 years (P = 005),
non-ambulatory performance status (ECOG PS ≥2;
P = 0036), platelet count of <100 9 109/l (P < 0001) and
high-risk IPI (P = 00053) (Figure 2B), as listed in Table III.
In addition, patients not achieving a CR after treatment for
transformation had a poorer survival (landmark 4 months;
P < 0001). In a multivariate analysis, including platelet
counts, IPI and response (age and performance status were
considered redundant with IPI), the variables that indepen-
dently predicted a worse SFT in the final model with 34
patients were IPI (low/intermediate-risk vs. high-risk; HR
5294; P = 0016) and CR achievement (CR vs. no CR; HR
0375; P < 0001).
Discussion
Transformation to high-grade lymphoma in low-grade B-cell
neoplasms such as FL and chronic lymphocytic leukaemia/
small lymphocytic lymphoma (CLL/SLL) is a well-recognised
feature in the natural history of these diseases. Data on trans-
formation in another less frequent low-grade lymphoma,
such as SMZL, are limited and poorly documented. Informa-
tion mainly derives from reports on small series of patients,
Table II. Clinico-biological features of the 36 patients with SMZL-T
at the time of transformation.
Characteristics N n (%)
Age >60 years 36 25 (69)
Females 36 23 (64)
B symptoms 35 24 (69)
ECOG Performance Status ≥2 35 11 (69)
Ann Arbor Stage III–IV 36 33 (92)
Bulky disease (>7 cm) in lymph nodes 30 8 (27)
Haemoglobin level <100 g/l 36 31 (86)
Platelet count <100 9 109/l 36 5 (14)
Raised LDH 33 23 (70)
Raised B2M 28 22 (79)
IPI high risk 35 29 (83)
Transformation time 36
At diagnosis 5 (14)
During follow-up* 31 (86)
B2M, b2-microglobulin; ECOG, Eastern Cooperative Oncology
Group; LDH, lactate dehydrogenase.
*Sites of transformation: 17 in one site: 11 in lymph node, four in
bone marrow, one in spleen and one in nasal septum; 14 in more
than one site: lymph node and bone marrow in six (four of them
with also extra-nodal involvement), lymph node and pleural effusion
in three, spleen, liver, pleural effusion and ascites in two, lymph
node and lip in one, spleen and bone marrow in one, and spleen,
bone marrow and lymph node in one.
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and it has been mainly focussed on limited histopathological
features11 and/or clinical manifestations.10,13
In the present study, we document the incidence of trans-
formation, the risk factors responsible for this aggressive
behaviour and the outcome of these patients in a series of
SMZL diagnosed or referred to our Institution. To date, this
is the largest series of patients with SMZL with a well-
documented histological transformation providing informa-
tion not only on the incidence and clinico-biological features
of these patients, but also on the potential risk factors that
predispose to this event.
As in other reports, DLBCL accounted for all our patients
with SMZL-T except for one that developed HL. IHC to
determine the cell of origin in transformed tissues showed
that the majority (72%) of patients studied had a non-GCB
phenotype. Rearrangements or gains of MYC, BCL6, and/or
BCL2 were present in six of the 14 investigated patients. Of
interest, one patient was EBV positive, a rare scenario that
has been previously reported in one patient.10 In our present
patient, related clonality was proven by the detection of the
same IGH rearrangement in the transformed and low-grade
tissues.
There are uncertainties regarding the incidence of trans-
formation in SMZL. In retrospective series of patients with
SMZL, transformation has been documented with a range of
11% to 19%.3,7,10–12,19,20 In contrast to these data, Conconi
et al.13 documented a 5% incidence of transformation at
5 years in 85 patients with SMZL and thus lower than that
previously reported. The shorter period of follow-up in the
Conconi et al.13 series may explain the lower rate of transfor-
mation in the study. Overall, most of the data, including our
present data, suggest that the incidence of transformation in
SMZL is about 10–15%, intermediate of what is seen in
CLL/SLL and FL.21,22
The presence of extrahilar lymph node involvement has
been suggested to be associated with transformation.10 Two
reports that included all types of MZL showed that raised
LDH,12,13 high-risk HPLL and IPI scores, and lack of
response to therapy predicted for a poor outcome in SMZL,
but these variables were not predictors for transformation.13
Early relapse has been associated with a worse outcome in
FL23 and recently in MZL24 but to date has not been linked
to transformation.
Our present data show that several clinical and biological
features at diagnosis such as cytopenias, hypoalbuminaemia,
high IIL and HPLL scores, lack of response to first-line
Fig 2. Survival from transformation in the 36 patients with SMZL-T.
(A) Overall survival from transformation, (B) Survival from transfor-
mation according to IPI. IPI, International Prognostic Index; SMZL-
T, splenic marginal zone lymphoma with transformation. [Colour
figure can be viewed at wileyonlinelibrary.com]
Table III. Univariate analysis for survival from transformation (SFT)
of the 36 patients with SMZL-T
Variable n
5-yearr
SFT, % HR (95% CI) P
Age, years
≤60 11 67
>60 25 34 33 (1–119) 005
ECOG performance status
0–1 25 58
≥2 11 14 27 (103–71) 0036
Platelet count, 9 109/l
≥100 5 30
<100 31 50 121 (25–585) <0001
IPI
Low–intermediate 14 75
High 21 26 52 (14–185) 0005
Response to therapy*
CR 22 69
No CR 11 11 245 (15–40) <0001
HR, hazard ratio; CI, confidence interval; IPI, International Prognos-
tic Index for aggressive lymphomas.
*For response to therapy a landmark analysis at 4 months was estab-
lished; therefore, patients with non-evaluable response (one patient)
or dying during this time (two) were excluded.
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treatment, relapse, and CK significantly predicted transfor-
mation in univariate analysis. However, the only feature that
remained significant in multivariate analysis was a CK. Fur-
thermore, a CK at diagnosis was also significantly associated
with a worse OS from diagnosis in the whole series. It is
known that a CK (three or more chromosomal aberrations)
or a high-risk CK (five or more chromosomal aberrations)
are very unfavourable prognostic factors in other B-cell neo-
plasms, such as CLL/SLL.25 The Splenic B-cell Lymphoma
Group retrospectively analysed the cytogenetic abnormalities
in 330 patients with SMZL and documented that an aberrant
karyotype with two or more abnormalities, 14q aberrations,
and 17p deletion were associated with a worse prognosis in
univariate analysis, but these abnormalities lost significance
in the multivariate analysis and their impact as a risk factor
for transformation was not investigated.26 Our present find-
ing on the association between a CK and poor outcome in
SMZL parallels that documented in CLL.25 For the first time,
we demonstrate that a CK at diagnosis is a strong predictor
for transformation and for a shorter OS in SMZL. This raises
the issue as to whether conventional cytogenetics should be
carried out in SMZL at diagnosis due to its major prognostic
impact in the disease course of this lymphoma.
Information on the clinical features and outcome of
SMZL-T is scarce. The clinical manifestations in our present
patients were similar to those previously documented by
others.13 We could not confirm that patients who trans-
formed exclusively in PB and BM had a poorer prognosis as
referred by Dungarwalla et al.10 However, this scenario was
very rare in our present series with only four patients having
isolated BM transformation.
Immunochemotherapy is the standard therapy for de novo
or transformed DLBCL. There are few reports on the manage-
ment of SMZL-T in the rituximab era. Dungarwalla et al.10
described two of nine patients receiving immunochemother-
apy and both achieved a CR. In the Else et al.20 series, of the
seven patients treated with rituximab and anthracycline-based
chemotherapy six achieved a CR and one a PR. In the Conconi
et al.13 series, responses were not recorded in the four patients
with SMZL-T that received regimens with rituximab and con-
solidation with an ASCT in two of them.
Our present series with a significantly larger number of
patients treated with rituximab-based regimens showed a
higher response rate to immunochemotherapy compared
with only chemotherapy (CR 67% vs. 50%), but this did not
translate into a survival benefit. The response rate to
immunochemotherapy in SMZL-T compares to that of trans-
formed FL (FL-T) and is superior to that in Richter transfor-
mation (RS) of CLL. However, and in contrast to SMZL-T
and RS of CLL, the use of anthracycline-based
immunochemotherapy in FL-T was associated with an
improvement in the outcome with an OS of 66% at
5 years.27,28
In summary, we describe the disease features, outcome,
incidence and risk factors for transformation in the most
extensive series ever reported of patients with SMZL that
underwent transformation to a high-grade lymphoma. Nota-
ble, is the finding of a CK at diagnosis that was not only a
significant predictive factor for a higher risk of transforma-
tion but also for worse survival in SMZL. Further studies
aimed at identifying potential molecular players responsible
for transformation of SMZL will be relevant and will shed
some light in the oncogenic mechanisms of such aggressive
behaviour.
Acknowledgments
This work was supported by grants from Fondo de Investi-
gaciones Sanitarias, Instituto de Salud Carlos III (PI17/
01061 to Sılvia Bea, PI19/00887 to Armando Lopez-
Guillermo), Fundacion AECC/CIBERONC (PROYE18020-
BEA to Sılvia Bea), and CIBERONC (CB16/12/00334 to
Dolors Colomer, and CB16/12/00225 to Elıas Campo),
Generalitat de Catalunya Suport Grups de Recerca AGAUR,
2017-SGR-709 (to Sılvia Bea) 2017-SGR-1009 (to Dolors
Colomer), 2017-SGR-1142 (to Elıas Campo), Ministerio de
Ciencia e Innovacion (MCI) [Grant No. RTI2018-094274-
B-I00 (to Elıas Campo)] and the European Regional Devel-
opment Fund ‘Una manera de fer Europa’. Elıas Campo is
an Academia Researcher of the ‘Institucio Catalana de
Recerca i Estudis Avancats’ (ICREA) of the Generalitat de
Catalunya. This work was partially developed at the Centro
Esther Koplowitz (CEK), Barcelona, Spain. We are grateful
to Miriam Prieto, Candida Gomez, Amparo Arias, and Sil-
via Martın for excellent technical assistance. We are also
very grateful to all patients with SMZL who have partici-
pated in this study.
Conflict of interest
Maria Joao Baptista is currently an AstraZeneca employee.
The remaining authors declare no competing financial inter-
ests.
Author contributions
Study conceptualization and design (Gabriela Bastidas-Mora,
Sılvia Bea, Armando Lopez-Guillermo, Estella Matutes). Data
collection and data review (Gabriela Bastidas-Mora, Sılvia
Bea, Alba Navarro, Dolors Costa, Neus Villamor, Dolors
Colomer, Monica Lopez-Guerra, Marıa Rozman, Olga
Balague, Daniel Martınez, Elıas Campo, Estella Matutes).
Analysis and interpretation (Gabriela Bastidas-Mora, Sılvia
Bea, Armando Lopez-Guillermo, Estella Matutes). Provision
of study material or patients (Eva Gine, Julio Delgado, Tycho
Baumann, Laura Magnano, Alfredo Rivas-Delgado, Maria
Joao Baptista, Lourdes Escoda, Miguel Alcoceba, Margarita
Blanes, Fina Climent, Andrew Wotherspoon, Armando
Lopez-Guillermo). All authors reviewed, edited, and
approved the manuscript.
Features and outcome of SMZL in transformation
ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. 9
Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
Fig S1. Overall survival from transformation in the 84
patients from the Hospital Clinic of Barcelona (HCB).
Table SI. Characteristics of 84 patients with splenic mar-
ginal zone lymphoma (SMZL) at diagnosis.
Table SII. Cytogenetics at diagnosis in the 54 of 69
patients with splenic marginal zone lymphoma (SMZL) from
the Hospital Clinic of Barcelona (HCB) who did not develop
transformation.
Table SIII. Risk factors for overall survival in the 84 sple-
nic marginal zone lymphoma (SMZL) Hospital Clinic of Bar-
celona (HCB) cohort (univariate analysis).
Table SIV. Characteristics at the time of diagnosis of the
21 patients with splenic marginal zone lymphoma with trans-
formation (SMZL-T) referred from other centres.
References
1. Armitage JO, Weisenburger DD. New approach to classifying non-
Hodgkin’s lymphomas: clinical features of the major histologic subtypes.
Non-Hodgkin’s lymphoma classification project. J Clin Oncol.
1998;16:2780–95.
2. Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL. Splenic marginal zone
lymphoma: a population-based study on the 2001–2008 incidence and sur-
vival in the United States. Leuk Lymphoma. 2013;54:1380–6.
3. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ,
Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma
with villous lymphocytes: a report on 129 patients. Br J Haematol.
2003;120:759–64.
4. Olszewski AJ. Survival outcomes with and without splenectomy in splenic
marginal zone lymphoma. Am J Hematol. 2012;87:E119–22.
5. Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, et al.
Splenic marginal zone lymphoma: a prognostic model for clinical use.
Blood. 2006;107:4643–9.
6. Montalban C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-
Vasco P, Iannitto E, et al. Risk stratification for Splenic Marginal Zone
Lymphoma based on haemoglobin concentration, platelet count, high lac-
tate dehydrogenase level and extrahilar lymphadenopathy: development
and validation on 593 cases. Br J Haematol. 2012;159:164–71.
7. Lenglet J, Traulle C, Mounier N, Benet C, Munoz-Bongrand N, Amorin S,
et al. Long-term follow-up analysis of 100 patients with splenic marginal
zone lymphoma treated with splenectomy as first-line treatment. Leuk
Lymphoma. 2014;55:1854–60.
8. Piris MA, Onaindıa A, Mollejo M. Splenic marginal zone lymphoma. Best
Pract Res Clin Haematol. 2017;30:56–64.
9. Thieblemont C, Davi F, Noguera ME, Briere J, Bertoni F, Zucca E, et al.
Splenic marginal zone lymphoma: current knowledge and future direc-
tions. Oncology. 2012;26194–202.
10. Dungarwalla M, Appiah-Cubi S, Kulkarni S, Saso R, Wotherspoon A, Osuji
N, et al. High-grade transformation in splenic marginal zone lymphoma
with circulating villous lymphocytes: the site of transformation influences
response to therapy and prognosis. Br J Haematol. 2008;143:71–4.
11. Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernandez JM,
et al. Progression to large B-cell lymphoma in splenic marginal zone lym-
phoma: a description of a series of 12 cases. Am J Surg Pathol.
2001;25:1268–76.
12. Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E,
et al. Risk factors for transformation to higher-grade lymphoma and its
impact on survival in a large cohort of patients with marginal zone lym-
phoma from a single institution. J Clin Oncol. 2018;36:3370–80.
13. Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-
Casaluci G, Stathis A, Moccia AA, et al. Histologic transformation in mar-
ginal zone lymphomas. Ann Oncol. 2015;26:2329–35.
14. Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A,
et al. Splenic marginal zone lymphoma proposals for a revision of diag-
nostic, staging and therapeutic criteria. Leukemia. 2008;22:487–95.
15. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM,
et al. Report of an international workshop to standardize response criteria
for non-Hodgkin’s lymphomas. NCI Sponsored International Working
Group. J Clin Oncol. 1999;17:1244.
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ,
et al. Revised response criteria for malignant lymphoma. J Clin Oncol.
2007;25:579–86.
17. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al.
WHO classification of tumours of haematopoietic and lymphoid tissues
(Revised 4th Edition). Lyon: IARC; 2017.
18. McGowan-Jordan J, Hastings RJ, Moore S, Editors. ISCN 2020: an inter-
national system for human cytogenomic nomenclature (2020). Basel,
Switzerland: S. Karger AG; 2020.
19. Xing KH, Kahlon A, Skinnider BF, Connors JM, Gascoyne RD, Sehn LH,
et al. Outcomes in splenic marginal zone lymphoma: analysis of 107
patients treated in British Columbia. Br J Haematol. 2015;169:520–7.
20. Else M, Marın-Niebla A, de la Cruz F, Batty P, Rıos E, Dearden CE, et al.
Rituximab, used alone or in combination, is superior to other treatment
modalities in splenic marginal zone lymphoma. Br J Haematol.
2012;159:322–8.
21. Alonso-Alvarez S, Magnano L, Alcoceba M, Andrade-Campos M,
Espinosa-Lara N, Rodrıguez G, et al. Risk of, and survival following, histo-
logical transformation in follicular lymphoma in the rituximab era. A ret-
rospective multicenter study by the Spanish GELTAMO group. Br J
Haematol. 2017;178:699–708.
22. Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, et al.
Biological and clinical risk factors of chronic lymphocytic leukaemia trans-
formation to Richter syndrome. Br J Haematol. 2008;142:202–15.
23. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al.
Early relapse of follicular lymphoma after rituximab plus cyclophos-
phamide, doxorubicin, vincristine, and prednisone defines patients at high
risk for death: an analysis from the national lymphocare study. J Clin
Oncol. 2015;33:2516–22.
24. Luminari S, Merli M, Rattotti S, Tarantino V, Marcheselli L, Cavallo F,
et al. Early progression as a predictor of survival in marginal zone
lymphomas: an analysis from the FIL-NF10 study. Blood. 2019;134:798–
801.
25. Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F,
et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions,
associations, and clinical impact. Blood. 2019;133:1205–16.
26. Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E,
et al. Cytogenetic aberrations and their prognostic value in a series of 330
splenic marginal zone B-cell lymphomas: a multicenter study of the Sple-
nic B-Cell Lymphoma Group. Blood. 2010;116:1479–88.
27. Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI,
et al. Rates and outcomes of follicular lymphoma transformation in the
immunochemotherapy era: a report from the University of Iowa/MayoCli-
nic specialized program of research excellence molecular epidemiology
resource. J Clin Oncol. 2013;31:3272–8.
28. Tsimberidou AM, O’Brien S, Khouri I, Giles FJ, Kantarjian HM,
Champlin R, et al. Clinical outcomes and prognostic factors in
patients with Richter’s syndrome treated with chemotherapy or
chemoimmunotherapy with or without stem-cell transplantation. J Clin
Oncol. 2006;24:2343–51.
G. Bastidas-Mora et al.
10 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
